

1           **Clinical Assessment of the Utility of Metagenomic Next-Generation**  
2           **Sequencing in Pediatric Patients of Hematology Department**

3

4

5 Heping Shen<sup>1</sup>, Diying Shen<sup>1</sup>, Hua Song<sup>1</sup>, Xueqin Wu<sup>2</sup>, Cong Xu<sup>2</sup>, Guangyu  
6 Su<sup>2</sup>, Chao Liu<sup>2\*</sup>, Jingying Zhang<sup>1\*</sup>

7

8 Author affiliations:

9 1. The Children's Hospital, Zhejiang University School of Medicine, National  
10 Clinical Research Center for Child Health. Hangzhou, Zhejiang, China  
11 310003

12 2. Hangzhou Matrix Biotechnology Co., Ltd, Bd 5, 208 Zhenzhong Rd,  
13 Hangzhou, Zhejiang, China 310030

14

15 Corresponding author:

16 Dr. Chao Liu, Director of Medical Department, Hangzhou Matrix  
17 Biotechnology Co., Ltd, Bd 5, 208 Zhenzhong Rd, Hangzhou, Zhejiang, China  
18 310030. Email: zenith.fenix@gmail.com

19

20 Dr. Jingying Zhang, The Children's Hospital, Zhejiang University School of  
21 Medicine, National Clinical Research Center for Child Health, Hangzhou,  
22 Zhejiang, China 310003, Email: zangjy423 @zju.edu.cn

23

24           **Running title**

25 Assessment of metagenomic sequencing for diagnosing infection in  
26 hematological patients

27

28           **Keywords**

29 Metagenomic Next-Generation Sequencing, Diagnosis, Pediatric,  
30 Hematological malignancy, Infectious disease

31

32 Abstract word count: 223. Text word count: 2387. Number of figures: 1.

33 Number of tables: 2 main, 1 supplemental.

34

35

36

37

## 38 **Abstract**

39 Metagenomic Next-Generation Sequencing (mNGS) is an emerging technique  
40 for microbial identification and diagnosis of infectious diseases. The clinical  
41 utility of mNGS in management of infections, especially its real-world impact  
42 on antimicrobial therapy and patient outcome has not been systematically  
43 evaluated. To that end, we prospectively assessed the effectiveness of mNGS  
44 in 70 febrile inpatients with suspected infections at Hematology department of  
45 the Children's Hospital, National Clinical Research Center for Child Health.  
46 69/70 patients were given empirical antibiotics prior to mNGS. A total of 104  
47 samples (62 plasma, 34 throat swabs, 4 bone marrow, 4 bronchoalveolar  
48 lavage) were collected on day 1-28 (mean 6.9) after symptom onset and  
49 underwent mNGS testing. Traditional microbial tests such as culture identified  
50 causal microorganisms in 5/70 (7.14%) patients that were in accordance with  
51 mNGS. In addition, mNGS reported possible pathogens when routine tests  
52 were negative. Antimicrobial treatment was adjusted in 55/70 (78.6%) patients  
53 that led to improvement/relief of symptoms within 3 days. On the other hand, in  
54 15/70 (21.4%) patients, mNGS reports were considered irrelevant by a board  
55 of clinicians based on biochemical, serological, imaging evidence and  
56 experiences. We concluded that mNGS not only expanded clinical capacity of  
57 pathogen detection, but also yielded positive impact on handling suspected  
58 infections through 1) differential diagnosis which may rule out infectious  
59 diseases and 2) modification and de-escalation of empirical antibiotic regimen.  
60

## 61 **Introduction**

62 Clinical management of microbial infection is a leading factor that influences  
63 prognosis of pediatric patients with hematological malignancies including  
64 acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML),  
65 non-Hodgkin lymphoma (NHL), aplastic anemia (AA), blastic plasmacytoid  
66 dendritic cell neoplasm (BPDCN) [1-3]. Early diagnosis and intervention of  
67 infectious diseases would drastically reduce the risk of complications and  
68 improve patients' long-term survival rate [4]. As a result, diagnostic tests play a  
69 critical role in clinical care of hematological patients with suspected infections,  
70 especially when empirical antibiotic treatment is not effective. However,  
71 traditional microbiological techniques such as culture, staining and serology  
72 often have low sensitivity and can only cover a small fraction of potential  
73 pathogens [5].

74 With the development of Massively Parallel Sequencing (MPS) technologies,  
75 sequencing-based diagnostics such as the metagenomic Next Generation  
76 Sequencing (mNGS) are increasingly applied clinically. mNGS test is  
77 "culture-free" and "hypothesis-free" that can encompass a wide range of  
78 pathogens in a single test [6]. Compared to contemporary microbiological  
79 methods, mNGS has the advantage of diagnosing polymicrobial infections,

80 fastidious and unculturable or even novel pathogens within a time frame of  
81 24-48 hours [7]. As a nucleic acid test (NAT), mNGS has fairly high sensitivity  
82 and specificity and is generally less-affected by antibiotic use than culture [8,  
83 9].

84 Despite its technological potential, mNGS has several drawbacks that might  
85 hinder its application in a clinical setting. These include but are not limited to  
86 high cost, slow turn-around-time (TAT), lack of assay standards and  
87 challenges in interpretation of reported microorganisms. Clinicians' opinions  
88 towards the utility of mNGS are quite polarized. While many studies pointed  
89 out its value in diagnosing infections in immunocompromised cohort, a number  
90 of studies suggested limited utility of mNGS as currently used in routine clinical  
91 practice [10, 11]. The divergent views on mNGS and its real-world impact  
92 partly reflect the complexity of infectious diseases management and how to  
93 integrate mNGS into patient treatment. There are many factors at play, such as  
94 sample type, TAT, prior use of antibiotics, prevalence of antimicrobial  
95 resistance, patient's age, ethnicity, gender, underlying illness, *etc.* [12]

96 In order to experience and assess whether and how mNGS can benefit  
97 patient outcomes, we incorporated mNGS as a routine microbiological test in  
98 the Department of Hematology at Children's Hospital in Zhejiang Province,  
99 China. A total of 70 febrile pediatric patients with varying hematological  
100 diseases participated in this study. Most subjects were immunocompromised  
101 due to chemotherapy, hematopoietic stem cell transplantation and underlying  
102 conditions. Samples were collected and sent out for mNGS testing with most  
103 reports returned in less than 24 hours. For 38 patients who exhibited signs of  
104 respiratory infection (cough, shortness of breath, chest pain *etc.*), both  
105 respiratory sample (throat swab or bronchoalveolar lavage (BALF)) and  
106 peripheral blood were obtained. Routine clinical examinations such as chest  
107 CT scan, microbiological culture, blood cell count, biochemistry (PCT, hs-CRP,  
108 cytokines), serology (Flu A, Flu B, HPIV, AdV, RSV, EBV and CMV) and  
109 molecular (*Mycoplasma pneumoniae*) tests were performed in conjunction with  
110 mNGS. Prior to mNGS, 69/70 patients were empirically administered  
111 broad-spectrum antibiotics, but no apparent symptom relief was observed. The  
112 empirical antibiotic regimen typically comprised of meropenem, linezolid and  
113 voriconazole that targeted gram-negative, gram-positive bacteria and fungi,  
114 respectively. Antifungals were routinely used as a prophylaxis in hematological  
115 patients, which was deemed as a gold standard for preventing invasive fungal  
116 infections [13].

117 To interpret whether microorganisms reported by mNGS were of clinical  
118 relevance, we decided to evaluate the results according to the following criteria:  
119 we considered findings to be clinically relevant if 1) mNGS detected the same  
120 pathogens as shown in microbial culture/PCR; 2) patient's symptoms improved  
121 within 3 days upon adjusting or de-escalating antibiotics based on mNGS; 3)  
122 mNGS discovered pathogens that have already been covered by existing  
123 antibiotics and patient's symptoms relieved within 3 days; 4) mNGS was

124 negative and final diagnosis indicated diseases not associated with microbial  
125 infection (*i.e.* drug fever, tumor, autoimmune diseases *etc.*). On the other hand,  
126 we considered mNGS results to be irrelevant if 1) it reported bacteria or fungi  
127 but the patient recovered by imposing antifungal or antibacterial treatment,  
128 respectively; 2) mNGS reported potential pathogens but no improvement was  
129 observed by altering antibiotics. In cases where more than one type of sample  
130 was tested (*i.e.* throat swab and blood), reports from both samples were  
131 compared and taken into consideration.

132

## 133 **Methods**

### 134 **Subject recruitment**

135 From May 2019 to October 2019, 70 patients (43 males, 27 females) at  
136 Hematology department of the Children's Hospital, Zhejiang University School  
137 of Medicine, National Clinical Research Center for Child Health were recruited  
138 for this study. All participants were suspected of having infectious diseases  
139 due to fever and/or respiratory/gastrointestinal symptoms such as cough,  
140 shortness of breath, chest pain, diarrhea and abdominal pain *etc.* All subjects  
141 have provided informed consent for participation and publication of the  
142 de-identified data.

143

### 144 **Sample collection and mNGS testing**

145 For each patient, 10 mL of peripheral blood was drawn into EDTA tube.  
146 Sample collection took place on day 1-28 (mean 6.9) following onset of fever.  
147 Throat swab or 10 mL of BALF was collected if respiratory symptoms were  
148 present. In 4 patients, bone marrow aspiration was performed, and 2 mL of  
149 bone marrow was acquired instead of blood. Following collection, all samples  
150 were immediately sent to Hangzhou Matrixx Biotechnology Co., Ltd. for mNGS  
151 testing (PDC-seq<sup>TM</sup>). Whole blood was centrifuged at 1600g for 10 min and  
152 supernatant was centrifuged at 16000g for 10 min to obtain plasma. For  
153 plasma and bone marrow, DNA sequencing was performed. For throat swab  
154 and BALF, RNA sequencing was also performed in order to detect RNA viruses,  
155 which are common in community-acquired respiratory infections. Following  
156 nucleic acid extraction, DNA or RNA library was prepared by reverse  
157 transcription (RNA only), enzymatic fragmentation (except for plasma), end  
158 repairing, terminal adenylation and sequencing adaptor ligation (NGSmaster<sup>TM</sup>  
159 library preparation, Matrixx, Cat# MAR002). Sequencing libraries were  
160 quantified by real-time PCR (KAPA) and pooled. Shotgun sequencing was  
161 carried out on illumina Nextseq<sup>TM</sup> platform. Approximately 20 million of 75bp  
162 single-end reads were generated for each library. Bioinformatic analysis was  
163 conducted as described in a previous report [14] in which sequences of human  
164 origin were filtered (GRCh38.p13) and the remaining reads were aligned to a  
165 microbial reference database (NCBI GenBank and in-house curated microbial  
166 genomic data) in order to identify species and relative abundance. For each

167 sequencing run, one negative control (artificial plasma mixed with fragmented  
 168 human genomic DNA) and one positive control (a mixture of inactivated  
 169 bacteria, fungi and pseudoviral particles containing synthesized DNA or RNA  
 170 fragments of adenovirus and influenza A virus, respectively) were included.  
 171

## 172 Results

### 173 Clinical characteristics

174 In this study, 51/70 (72.9%) participants were under 10 years old. All  
 175 patients have been previously diagnosed with hematological diseases. In  
 176 particular, 46 patients had acute lymphoblastic leukemia (ALL), 8 had acute  
 177 myeloid leukemia (AML), 13 had non-Hodgkin lymphoma (NHL), 1 had aplastic  
 178 anemia (AA), 1 had blastic plasmacytoid dendritic cell neoplasm (BPDCN) and  
 179 1 had immunodeficiency disease (IDD). Patients' samples were collected for  
 180 mNGS testing at day 1-28 ( $6.9 \pm 4.9$ ) following symptom onset (**Table 1** and  
 181 **Supplemental Table 1**). Results of clinical examinations were shown in **Table**  
 182 **2**. Notably, 36/70 (51.43%) had abnormally low neutrophil count (neutropenia),  
 183 which is typical in hematological patients [15].  
 184

185 **Table 1. Clinical characteristics of study participants.**

		Count	Ratio
Gender	Male	43	61.40%
	Female	27	38.60%
Age (years)	≥10	19	27.10%
	<10	51	72.90%
Sample type	Blood	62	59.62%
	Nasopharyngeal swab	34	32.69%
	Bronchoalveolar lavage	4	3.85%
	Bone marrow	4	3.85%
Underlying disease	ALL	46	65.71%
	NHL	13	18.57%
	AML	8	11.43%
	AA	1	1.43%
	BPDCN	1	1.43%
	IDD	1	1.43%
Neutropenia	Agranulocytosis	36	51.43%
	Normal	34	48.57%
Chest CT scan	Abnormal	30	42.86%
	No abnormalities	40	57.14%
Clinical outcome	Recovered	69	98.57%

	Deceased	1	1.43%
--	----------	---	-------

186 Abbreviations: acute lymphoblastic leukemia (ALL), acute myeloid leukemia  
 187 (AML), non-Hodgkin lymphoma (NHL), aplastic anemia (AA), blastic  
 188 plasmacytoid dendritic cell neoplasm (BPDCN), immunodeficiency disease  
 189 (IDD).  
 190

191 **Table 2. Routine laboratory test results.**

Test	Count
WBC	0.01 - 19.14 (3.38) x10 <sup>9</sup> /L
Neutrophill	0 - 10.9 (1.63) x10 <sup>9</sup> /L
hs-CRP	0.5 - 177.88 (43.42) mg/L
PCT	0.065 - 2.43 (0.36) ng/mL
IL-6	4 - 397.1 (73.17) pg/mL
IL-10	2.2 - 266.2 (18.74) pg/mL
γ-INF	1 - 116.3 (10.28) pg/mL
TNF	1 - 24.6 (2.53) pg/mL

192

193 **Microbiological testing and clinical impact**

194 Blood culture and *Mycoplasma pneumoniae* (MP) RNA test reported  
 195 positive findings in 5/70 (7.14%) patients. Particularly, blood culture identified 1  
 196 case of *Pseudomonas aeruginosa*, 1 case of *Klebsiella pneumoniae* and 1  
 197 case of *Staphylococcus epidermidis* while MP RNA test identified 2 positive  
 198 cases (1 from throat swab and the other from BALF). These microbial findings  
 199 were also reported by mNGS (**Supplemental Table 1**). Serology tests  
 200 identified 3 case of EBV (1/3 reported by mNGS), 2 case of CMV (1/2 reported  
 201 by mNGS), 1 case of *Aspergillus fumigatus* (not reported by mNGS), 1 case of  
 202 HPIV (not reported by mNGS since RNA sequencing was not performed for  
 203 plasma).

204 In total, 104 samples (62 plasma, 34 throat swabs, 4 bone marrow, 4 BALF)  
 205 were tested. mNGS on 47/62 plasma, 34/34 swab, 3/4 bone marrow, 4/4 BALF  
 206 reported positive microbial findings, respectively (**Figure 1**). For 34 patients  
 207 whose blood and swab were both tested, mNGS detected overlapping  
 208 microorganisms in 14/34 (41.18%) patients, including human herpesviruses (5  
 209 cases of EBV, 1 case of HSV-1, 1 case of HHV-7), human parvovirus B19 (3  
 210 cases), *Pseudomonas aeruginosa* (2 cases), *Acinetobacter baumannii* (1  
 211 case), *Staphylococcus aureus* (1 case), *Haemophilus parainfluenzae* (1 case)  
 212 and *Candida albicans* (1 case). For 4 patients whose blood and BALF were  
 213 collected, mNGS reported overlapping microorganisms in 2/4 (50%) (1 case of  
 214 *Mycoplasma pneumoniae* and 1 case of human parvovirus B19)  
 215 (**Supplemental Table 1**).

216 In 55/70 (78.57%) patients, mNGS findings led to positive impact on patient  
 217 outcome through adjusting or de-escalating empirical antibiotics. Notably, for

218 two patients with osteomyelitis, all microbial tests were negative except that  
219 plasma mNGS reported *Staphylococcus aureus*. Both patients recovered after  
220 applying anti-G+ bacteria treatment, including Vancomycin and Linezolid. In  
221 another patient with recurrent fever, plasma mNGS reported *Staphylococcus*  
222 *aureus* when routine tests were inconclusive. We adjusted antibiotics  
223 accordingly and the patient's fever subsided. However, fever recurred after  
224 drug withdrawal and a second blood culture was able to identify  
225 *Staphylococcus aureus*, which was consistent with the earlier mNGS result.  
226 Moreover, in two cases where mNGS was negative, one patient was  
227 diagnosed with hemophagocytic histiocytosis and the other was diagnosed  
228 with myelodysplastic syndrome, both of which were not associated with  
229 microbial infection. Antibiotics were de-escalated based on mNGS results in  
230 both cases.

231 On the other hand, in 15/70 (21.43%) patients, mNGS either reported  
232 microorganisms that were deemed irrelevant (1 case of neoplastic fever, 2  
233 cases of graft rejection after hematopoietic stem cell transplantation, 3 cases  
234 of bacterial enteritis) or failed to identify the causal pathogens when other tests  
235 and clinical evidence strongly suggested microbial infection (5 cases of  
236 pneumocystis pneumonia, 2 cases of pulmonary aspergillosis) (**Supplemental**  
237 **Table 1**).

238

## 239 Discussion

### 240 Clinical value of mNGS in diagnosing infectious disease

241 Failure or delay in identifying the microorganisms responsible for critical  
242 infection could lead to prolonged hospitalization and elevated death rate [16].  
243 Patients with hematological disorders are immunodeficient due to  
244 chemotherapy, hematopoietic cell transplantation and therefore are prone to  
245 opportunistic infections. In these patients, the causal pathogens may consist of  
246 a wide range of microbes, including bacteria, fungi and viruses. Due to  
247 frequent use of broad-spectrum antibiotics and clinical prevalence of fastidious  
248 microorganisms, microbial culture often fails to detect the culprit. Typically, the  
249 positive detection rate of blood culture is less than 10% [17]. In this study, the  
250 detection percentage was 5.71% (4/70). In contrast, mNGS is  
251 culture-independent and hypothesis-free that can theoretically detect over  
252 10000 pathogens of known genomic sequences. The technical detection rate  
253 of mNGS (percentage of mNGS reports that show potential pathogens) in our  
254 study was 88/104 (84.62%), making it a valuable tool for diagnosis of  
255 polymicrobial and rare infections, especially for immunocompromised patients.

256 In addition to bacteria and fungi, mNGS identified a variety of DNA and RNA  
257 viruses from all sample types, including adenovirus, rhinovirus, parainfluenza  
258 virus, human parvovirus B19, polyomaviruses (*Trichodysplasia spinulosa*  
259 polyomavirus, JC virus, BK virus) and human herpesviruses (HSV-1, HSV-2,  
260 EBV, CMV, HHV-6 and HHV-7), which were of clinical value since we normally

261 lacked diagnostic tests for these viruses (**Figure 1**). Prior to mNGS, antiviral  
262 treatment was not as much considered as compared to bacterial and fungal  
263 infections. Using mNGS, we were able to consider the possibility of viral  
264 infections and decide early on whether antivirals were necessary. In addition,  
265 the high incidence of herpesviruses as shown in our cohort was consistent with  
266 previous findings in which these viruses are common even in healthy  
267 individuals. However, it has been proposed that there exists a dynamic  
268 interaction between host immunity and herpesviruses that may influence the  
269 outcome of concurrent infections, cancers and grafts [18]. The clinical  
270 implications of herpesviruses in immunodeficient patients need further  
271 explorations.

272

### 273 **Sampling is critical for interpretation and utility of mNGS**

274 Plasma mNGS was of greater significance in helping clinicians determine  
275 the causal pathogen(s) as compared with throat swab, in which commensal  
276 microbiota from upper respiratory tract were present. Cell-free nucleic acid in  
277 plasma is thought to originate from apoptotic human cells and shedding of  
278 microbial nucleic acid from site of infection through interactions between the  
279 host immune system and invading pathogens [19]. In our study, 38/70 (54.29%)  
280 patients were suspected of respiratory infection due to symptoms such as  
281 cough and shortness of breath. Indeed, previous studies also suggest that  
282 respiratory tract infection (RTI) is one of the most frequently-encountered type  
283 of infection in hematological patients [20]. While BALF was of great value in  
284 diagnosing pulmonary infections, performing bronchoscopy on pediatric  
285 patients is not as frequent as in adults. Hematological patients often have low  
286 platelet count, further limiting the application of invasive procedures. Moreover,  
287 plasma mNGS has a higher likelihood of yielding false-negative results due to  
288 interference of host DNA background. Taken together, when bronchoscopy  
289 was not an option, collecting both throat swab and blood appeared to be a  
290 working strategy. As shown in our study, matching organism(s) from throat  
291 swab and plasma were identified in 14/34 (41.18%) patients (highlighted in red,  
292 **Supplemental Table 1**). It would also benefit patients when blood mNGS  
293 showed negative results, since throat swab can serve as a “backup” under this  
294 circumstance.

295

### 296 **When to use mNGS**

297 The turnaround time (TAT), cost and interpretation of results are important  
298 factors to consider before application of mNGS in a clinical setting.  
299 Furthermore, nucleic acid extraction seemed to be another key element to  
300 ensure sensitivity towards pathogens with thick cell walls or capsules that  
301 prevent efficient release of nucleic acid for downstream sequencing. This is  
302 especially evident when it comes to fungi as mNGS appeared to have missed  
303 5 cases of pneumocystis pneumonia and 2 cases of pulmonary aspergillosis.  
304 Fungal cell walls comprise of N-acetylglucosamine polymer chitin and



305 extraction techniques such as bead-beating and sonication might be desirable  
306 for effective detection of these pathogens.

307 To summarize, we found mNGS to be of clinical value and can benefit  
308 hematological patients in the following scenarios: 1) patients in critical  
309 condition with suspected infection and effective treatment is urgently needed;  
310 2) patients with immunosuppression or neutropenia that make them more  
311 disposed to polymicrobial infections; 3) routine microbiological tests are  
312 repeatedly inconclusive and empirical antibiotic treatment is unsuccessful; 4)  
313 recurrent of persistent fever of unknown origin in which differential diagnosis is  
314 needed to confirm or rule out microbial infection.

315

## 316 **References**

- 317 1. Ruiz Camps, I. and J. Aguilar Company, *Top-ten infections in onco-hematological*  
318 *patients (2015-2017)*. Rev Esp Quimioter, 2018. **31 Suppl 1**: p. 47-51.
- 319 2. Gedik, H., et al., *Bloodstream infections in patients with hematological malignancies:*  
320 *which is more fatal - cancer or resistant pathogens?* Ther Clin Risk Manag, 2014. **10**:  
321 p. 743-52.
- 322 3. Safdar, A. and D. Armstrong, *Infections in patients with hematologic neoplasms and*  
323 *hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects*.  
324 Clin Infect Dis, 2011. **53**(8): p. 798-806.
- 325 4. Abe, T., et al., *In-hospital mortality associated with the misdiagnosis or unidentified*  
326 *site of infection at admission*. Crit Care, 2019. **23**(1): p. 202.
- 327 5. Lee, A., et al., *Detection of bloodstream infections in adults: how many blood cultures*  
328 *are needed?* J Clin Microbiol, 2007. **45**(11): p. 3546-8.
- 329 6. Wilson, M.R., et al., *Actionable diagnosis of neuroleptospirosis by next-generation*  
330 *sequencing*. N Engl J Med, 2014. **370**(25): p. 2408-17.
- 331 7. Gu, W., S. Miller, and C.Y. Chiu, *Clinical Metagenomic Next-Generation Sequencing*

- 332            *for Pathogen Detection. Annu Rev Pathol*, 2019. **14**: p. 319-338.
- 333    8.        Zhang, X.X., et al., *The diagnostic value of metagenomic next-generation sequencing*
- 334            *for identifying Streptococcus pneumoniae in paediatric bacterial meningitis. BMC*
- 335            *Infect Dis*, 2019. **19**(1): p. 495.
- 336    9.        Wang, S., et al., *Diagnostic value and clinical application of next-generation*
- 337            *sequencing for infections in immunosuppressed patients with corticosteroid therapy.*
- 338            *Ann Transl Med*, 2020. **8**(5): p. 227.
- 339    10.        Hogan, C.A., et al., *Clinical Impact of Metagenomic Next-Generation Sequencing of*
- 340            *Plasma Cell-Free DNA for the Diagnosis of Infectious Diseases: A Multicenter*
- 341            *Retrospective Cohort Study. Clin Infect Dis*, 2020.
- 342    11.        Kufner, V., et al., *Two Years of Viral Metagenomics in a Tertiary Diagnostics Unit:*
- 343            *Evaluation of the First 105 Cases. Genes (Basel)*, 2019. **10**(9).
- 344    12.        Uyeki, T.M., et al., *Clinical Practice Guidelines by the Infectious Diseases Society of*
- 345            *America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional*
- 346            *Outbreak Management of Seasonal Influenzaa. Clin Infect Dis*, 2019. **68**(6): p.
- 347            895-902.
- 348    13.        Vazquez, L., *Antifungal Prophylaxis in Immunocompromised Patients. Mediterr J*
- 349            *Hematol Infect Dis*, 2016. **8**(1): p. e2016040.
- 350    14.        Miller, S., et al., *Laboratory validation of a clinical metagenomic sequencing assay for*
- 351            *pathogen detection in cerebrospinal fluid. Genome Res*, 2019. **29**(5): p. 831-842.
- 352    15.        Davis, K. and S. Wilson, *Febrile neutropenia in paediatric oncology. Paediatr Child*
- 353            *Health (Oxford)*, 2020. **30**(3): p. 93-97.

- 354 16. Mandell, L.A., et al., *Infectious Diseases Society of America/American Thoracic*  
355 *Society consensus guidelines on the management of community-acquired pneumonia*  
356 *in adults*. Clin Infect Dis, 2007. **44 Suppl 2**: p. S27-72.
- 357 17. Nannan Panday, R.S., et al., *Evaluation of blood culture epidemiology and efficiency*  
358 *in a large European teaching hospital*. PLoS One, 2019. **14**(3): p. e0214052.
- 359 18. Sehrawat, S., D. Kumar, and B.T. Rouse, *Herpesviruses: Harmonious Pathogens but*  
360 *Relevant Cofactors in Other Diseases?* Front Cell Infect Microbiol, 2018. **8**: p. 177.
- 361 19. Lee, R.A., et al., *Assessment of the Clinical Utility of Plasma Metagenomic*  
362 *Next-Generation Sequencing in a Pediatric Hospital Population*. J Clin Microbiol,  
363 2020.
- 364 20. Svensson, T., et al., *Utility of bronchoalveolar lavage in diagnosing respiratory tract*  
365 *infections in patients with hematological malignancies: are invasive diagnostics still*  
366 *needed?* Ups J Med Sci, 2017. **122**(1): p. 56-60.

367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384

385  
386  
387  
388  
389  
390

391 **Figure and Table legends**


392 **Figure 1. mNGS reports and clinical relevance.** A total of 104 samples (62  
393 plasma, 34 throat swabs, 4 bone marrow, 4 BALF) were collected for mNGS  
394 testing. 47/62 plasma, 34/34 swab, 3/4 bone marrow, 4/4 BALF reported  
395 positive microbial findings, respectively. The total counts of microorganisms of  
396 different categories and the number of microorganisms deemed  
397 clinically-relevant were shown (A) while the species information and count of  
398 viruses, fungi and bacteria detected from 4 different sample types were  
399 graphed (B).

400

401 **Supplemental Table 1. Clinical information of study participants.** Detailed  
402 clinical characteristics, laboratory test results, mNGS results and record of  
403 antibiotic use was listed for 70 patients. To protect the privacy of each  
404 participant, all identifying information was omitted.

# Figure 1

A



B

